Interest of (18)F‐FDG PET‐CT scanning for staging and management of merkel cell carcinoma: a retrospective study of 15 patients

Maury, Guy; Dereure, O.; Du‐Thanh, Aurélie; Mariano‐Goulart, Denis; Guillot, B.

doi:10.1111/j.1468-3083.2011.03994.x

Cited by 29 publications

(35 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our series, SSTR-PET was true negative in 6 SLN-negative patients and true positive in one SLN-positive patient but failed to demonstrate a 5 mm iliac lymph node metastasis in a patient who underwent complete lymph node dissection. Moreover, since neither SSTR- nor FDG-PET/CT consistently detects nodal MCC micro-metastases, these techniques are not intended to replace the sentinel lymph node biopsy [8,13,15]. However, if SSTR-PET detects unapparent lymph node metastases, as e.g.…”

Section: Discussionmentioning

confidence: 99%

Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging

et al. 2014

View full text Add to dashboard Cite

BackgroundMerkel cell carcinoma (MCC) is a rare cutaneous neoplasm with increasing incidence, aggressive behavior and poor prognosis. Somatostatin receptors (SSTR) are expressed in MCC and represent a potential target for both imaging and treatment.MethodsTo non-invasively assess SSTR expression in MCC using PET and the radiotracers [68Ga]DOTA-D-Phe1-Tyr3-octreotide (DOTATOC) or -octreotate (DOTATATE) as surrogate for tumor burden. In 24 patients with histologically proven MCC SSTR-PET was performed and compared to results of computed tomography (CT).ResultsSSTR-PET detected primary and metastatic MCC lesions. On a patient-based analysis, sensitivity of SSTR-PET was 73% for nodal metastases, 100% for bone, and 67% for soft-tissue metastases, respectively. Notably, brain metastases were initially detected by SSTR-PET in 2 patients, whereas liver and lung metastases were diagnosed exclusively by CT. SSTR-PET showed concordance to CT results in 20 out of 24 patients. Four patients (17%) were up-staged due to SSTR-PET and patient management was changed in 3 patients (13%).ConclusionSSTR-PET showed high sensitivity for imaging bone, soft tissue and brain metastases, and particularly in combination with CT had a significant impact on clinical stage and patient management.

show abstract

Section: Discussionmentioning

confidence: 99%

Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Most of the existing publications on PET in MCC were on series that included few patients (7)(8)(9)(10). At the time we designed the current study, the largest previously published series reporting the use 18 F-FDG PET in MCC was from Sydney, Australia, on 18 patients, of whom 12 underwent staging PET scans.…”

mentioning

confidence: 99%

¹⁸F-FDG PET Provides High-Impact and Powerful Prognostic Stratification in the Staging of Merkel Cell Carcinoma: A 15-Year Institutional Experience

et al. 2013

View full text Add to dashboard Cite

Merkel cell carcinoma (MCC) is a rare but aggressive skin cancer with limited evidence on the role of PET scanning. The primary aim of this study was to assess the impact of 18 F-FDG PET in the staging and management of MCC. Methods: A single-institution review using clinical outcome data collected until February 2012 was performed of patients with MCC who underwent staging PET scanning between January 1997 and October 2010. Management plans were recorded prospectively at the time of the PET request, and followup outcomes were recorded retrospectively. The clinical impact of PET was scored using our previously published criteria: "high" if the PET scan changed the primary treatment modality or intent; "medium" if the treatment modality was unchanged but the radiation therapy technique or dose was altered. The primary objective was to test the hypothesis that the true proportion of patients who have a high-or medium-impact scan would be greater than 25%. Results: The median follow-up of 102 consecutive patients was 4.8 y. The results of staging PET had an impact on patient management in 37% of patients (P , 0.003). High-and medium-impact scans were recorded for 22% and 15% of patients, respectively. PET staging results differed from conventional staging results in 22% of patients, with PET upstaging 17% and downstaging 5%. The 3-and 5-y overall survival was 60% (95% confidence interval, 50%-71%) and 51% (95% confidence interval, 41%-64%), respectively. In stratification by PET-defined stage, the 5-y overall survival was 67% for patients with stage I/II disease but only 31% for patients with stage III disease (log-rank P , 0.001). The 5-y cumulative incidence of locoregional failure, distant failure, and death was 16.6%, 22.3% and 14.3%, respectively. On multivariate analysis, only PET stage (P , 0.001) and primary treatment modality (P 5 0.050) were significantly associated with overall survival. The primary treatment modality was not associated with progression-free survival when stratification was by tumor stage. Conclusion: The use of 18 F-FDG PET scans had a great impact on patients and may play an important role in the prognostic stratification and treatment of this disease.

show abstract

“…Positron Emission Tomography ( 18 F-FDG-PET-CT) is an highly useful whole-body-staging method compared to conventional imaging methods, also when used as a single procedure [36, 37]. OctreoScan, using a labelled analogue of somatostatin ( 111 In-Pentetreotide), is still considered an highly sensitive method also when compared with other conventional imaging techniques [38].…”

Section: Resultsmentioning

confidence: 99%

Merkel Cell Carcinoma: A Retrospective Study on 48 Cases and Review of Literature

Cirillo

Vismarra

Cafaro

et al. 2012

Journal of Oncology

View full text Add to dashboard Cite

Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine tumor of the skin. Fourty-eight patients with MCC were observed at the Rare Hormonal Tumors Group of Cremona Hospital, 15 of these with unknown primary site. Due to rarity of Merkel cell carcinoma, clinical experience is generally limited. Data from our series confirm the current recommendations. Wide surgical excision must be associated with radiotherapy also in early stages in order to avoid local relapse and the rapid progression of disease. In advanced stages chemotherapy is the standard despite the short duration of responses and poor quality of life. The data of our series, characterized by a high demand for second opinion, offer some insight about the real rarity of the tumor, the difficulty of managing of disease in our country secondary to a wrong cultural approach to the problem, the indiscriminate use of molecules unnecessary and often expensive, the lack of protocols, and the presence of guidelines often ignored. This results in very poor survival associated with a very low quality of life, requiring to find the right direction towards a correct management of disease.

show abstract

Interest of (18)F‐FDG PET‐CT scanning for staging and management of merkel cell carcinoma: a retrospective study of 15 patients

Abstract: Although FDG PET-CT is of questionable value in MCC management when used in parallel with CT, it may be considered as a valuable option as a single whole-body survey procedure.

Cited by 29 publications

References 16 publications

Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging

Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging

¹⁸F-FDG PET Provides High-Impact and Powerful Prognostic Stratification in the Staging of Merkel Cell Carcinoma: A 15-Year Institutional Experience

Merkel Cell Carcinoma: A Retrospective Study on 48 Cases and Review of Literature

Contact Info

Product

Resources

About

Interest of (18)F‐FDG PET‐CT scanning for staging and management of merkel cell carcinoma: a retrospective study of 15 patients

Abstract: Although FDG PET-CT is of questionable value in MCC management when used in parallel with CT, it may be considered as a valuable option as a single whole-body survey procedure.

Cited by 29 publications

References 16 publications

Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging

Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging

18F-FDG PET Provides High-Impact and Powerful Prognostic Stratification in the Staging of Merkel Cell Carcinoma: A 15-Year Institutional Experience

Merkel Cell Carcinoma: A Retrospective Study on 48 Cases and Review of Literature

Contact Info

Product

Resources

About

¹⁸F-FDG PET Provides High-Impact and Powerful Prognostic Stratification in the Staging of Merkel Cell Carcinoma: A 15-Year Institutional Experience